Tuesday, February 09, 2021 9:23:05 AM
Agenus Announces New Responses for AGEN1181
-- 6 total confirmed objective clinical responses in colon, ovarian, and
endometrial cancers
-- No complement-mediated toxicities reported
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced additional confirmed objective clinical responses from its Phase 1/2 trial of AGEN1181, its next-generation anti-CTLA-4, as monotherapy and in combination with Agenus' anti-PD-1 balstilimab.
"These are very exciting results which demonstrate the potential of AGEN1181 as an efficacious next-generation CTLA-4 antibody. AGEN1181 is showing activity in difficult-to-treat tumors without the neuroendocrine or significant liver toxicities commonly observed with the currently-approved CTLA-4 antibody ipilimumab," said Dr. Steven O'Day, Chief Medical Officer at Agenus. "The responses seen in patients with ovarian and MSS colorectal cancer are particularly encouraging given the generally low activity seen with immunotherapy in these indications."
The Phase 1 dose escalation trial has had no reports of complement-mediated toxicities. These are severe toxicities associated with first-generation CTLA-4 antibodies. The trial has also defined the optimal combination dose for AGEN1181 +/- balstilimab.
Agenus also presented on the first-ever report of intratumoral Treg depletion with a CTLA-4 antibody in clinical trials at SITC 2020.
The summary of responses with AGEN1181 alone or in combination with balstilimab are as follows:(1)
-- CR in PD-L1(-) MSS endometrial cancer patient (1181 monotherapy)
-- CR by PET in PD-L1(-) MSS endometrial cancer patient (1181 + bal)
-- PR in PD-L1(-) refractory ovarian cancer patient (1181 + bal)
-- PR in colorectal cancer patient (1181 + bal)
-- PR in MSS colorectal cancer patient (1181 + bal) -- new confirmed
response
-- PR in ovarian cancer patient (1181 + bal) -- new confirmed response
AGEN1181 alone and in combination with balstilimab has expanded dosing into colorectal cancer. Phase 2 trials in additional cancer indications are scheduled to commence shortly.
Recent AGEN News
- The Gross Law Firm Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 09/23/2024 09:45:00 AM
- Contact The Gross Law Firm by November 5, 2024 Deadline to Join Class Action Against Agenus Inc.(AGEN) • PR Newswire (US) • 09/19/2024 09:45:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) Shareholders • PR Newswire (US) • 09/16/2024 09:45:00 AM
- Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024 • Business Wire • 09/13/2024 02:00:00 PM
- Edelson Lechtzin LLP Urges Agenus, Inc. (NASDAQ: AGEN) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action • PR Newswire (US) • 09/11/2024 06:25:00 PM
- Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 • Business Wire • 09/09/2024 11:30:00 AM
- Agenus to Participate in September Investor Conferences • Business Wire • 09/03/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:49:59 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/08/2024 08:47:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:45:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:45:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:08:46 PM
- Agenus Reports Second Quarter 2024 Operational and Financial Results • Business Wire • 08/08/2024 11:00:00 AM
- Agenus Announces Appointment of Tom Harrison to Board of Directors • Business Wire • 08/08/2024 11:00:00 AM
- Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers • Business Wire • 08/07/2024 02:58:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:02:09 PM
- Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update • Business Wire • 07/26/2024 11:00:00 AM
- Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer • Business Wire • 07/18/2024 11:00:00 AM
- Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference • Business Wire • 06/28/2024 03:10:00 PM
- Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies • Business Wire • 06/27/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:05:01 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM